主髂动脉闭塞合并股总动脉受累的杂交血运重建早期结果
单中心前瞻性研究纳入98例TASC-II C/D级主髂动脉闭塞合并股总动脉受累的严重肢体缺血患者,采用髂动脉支架联合股动脉内膜剥脱的杂交血运重建。技术成功率98%,30天通畅率100%,中位随访18个月一期通畅率87.2%,累积一期辅助及二期通畅率93.4%,总体并发症率16.3%,30天无死亡。
要点
- 杂交血运重建治疗主髂动脉合并股总动脉病变技术成功率高、早期通畅好。
- 30天通畅率100%,无30天死亡及血栓相关再干预。
- 中位18个月一期通畅率87.2%,累积一期辅助及二期通畅率93.4%。
核心结论
- 杂交血运重建是治疗主髂动脉闭塞合并股总动脉受累安全且创伤较小的方式,早期通畅结果好、主要并发症率低,可作为传统开放手术的优良替代,尤其适用于高危患者。
研究设计与样本
- 单中心前瞻性研究,2017年1月至2020年9月在Ivano-Frankivsk区域临床医院纳入98例TASC-II C和D级主髂动脉闭塞合并股总动脉受累的严重肢体缺血患者,采用髂动脉支架联合股动脉内膜剥脱的杂交血运重建。
主要发现
- 患者平均年龄65±7.2岁,男性61例、女性37例,TASC-II D级病变占77%。
- 技术成功率为98%,2例因腔内病变通过时无法重回主动脉真腔而行股-股交叉旁路术。
- 30天无死亡,无因血栓形成的再干预,30天通畅率100%。
- 19例(19.3%)因远端闭塞及轻/重度组织丢失需额外延期旁路手术,总体并发症率16.3%(16例)。
- 中位随访18个月(范围1-36个月),一期通畅率87.2%,累积一期辅助及二期通畅率93.4%,研究期间4例死亡。
临床怎么用
- 对于主髂动脉闭塞合并股总动脉受累的严重肢体缺血患者,尤其高危人群,可考虑髂动脉支架联合股动脉内膜剥脱的杂交血运重建。
- 术后需关注远端闭塞及组织丢失患者可能需额外延期旁路手术。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To study the early outcomes of aorto-iliac occlusive disease with common femoral artery involvement by hybrid methods of revascularization - iliac stenting with femoral endarterectomy. We report the initial experiences of a single centre and discuss issues that arose. METHODS: Ninety-eight critical limb ischaemia (CLI) patients with aorto-iliac occlusive lesions TASC-II C and D were treated using HR between January 2017 and September 2020 in the Ivano-Frankivsk Regional Clinical Hospital. Prospective data were recorded and analysed including demographics, technical success, 30-day and early patency outcomes, re-intervention, and death. RESULTS: The mean age of patients was 65 ± 7.2 years (61 men and 37 women). Using classification by TASC-II, 77% of the lesions were class D. Technical success was seen in 98% of patients. Two patients underwent a crossover femoro-femoral bypass due to failure to re-enter the true lumen of the aorta during endovascular lesion crossing. There were no deaths during the 30-day period. No re-interventions for thrombosis were needed. Additional delayed bypass procedures were required in 19 patients (19.3%) with distal occlusions and minor and major tissue loss. The overall complication rate was 16.3% (16 patients). The 30-day patency rate was 100%. The median follow-up period was 18 months (range 1-36 months) with a primary patency rate of 87.2%, and cumulative primary assisted and secondary patency rate of 93.4%. Four patients died during the study period. CONCLUSIONS: Hybrid revascularization is a safe and less traumatic method of managing aorto-iliac occlusive disease with common femoral artery involvement. Good early patency results and low major complication rates indicate that HR is an excellent alternative to traditional open surgery, especially for high-risk patients.
引用
- Gudz O, Gudz I, Gintchitsky V, et al. Hybrid Revascularization for Aorto-Iliac Occlusive Disease with Common Femoral Artery Involvement: Early Outcomes of a Single Centre. Ann Vasc Surg. 2021. PMID: 34656721. doi:10.1016/j.avsg.2021.07.054
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。